C5 and paroxysmal nocturnal hemoglobinuria: New therapeutic strategies, including anti-sense oligonucleotides (ASO) or RNAi therapeutics, have the potential to transform treatment options for aHUS and PNH patients by achieving long-term knockdown of C5 expression in the liver.